Minerva Licenses Osmetech's SAM Tech to Study Functional Proteomics

Jun 28, 2007

NEW YORK (GenomeWeb News) — Minerva Biotechnologies has non-exclusively licensed Osmetech’s self-assembling monolayer technology for use with its proprietary nanoparticle technology, Osmetech said today.

Osmetech said Minerva will use the SAM technology to study signal enhancement, drug design, drug screening, and functional proteomics.

Osmetech exclusively licensed the technology from Harvard University a decade ago. The IP was invented in part by Minerva founder and CSO Cynthia Bamdad.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Featured White Papers

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Albumin Removal Reference Applications

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Main menu